Beyond RNAi: The Expanding Architecture of RNA Technologies in Agriculture
Several developments across agricultural RNA have landed in quick succession this year. Taken individually, they look like routine industry news. Taken together, they suggest something bigger is underway.
Syngenta introduced EXORT™, a microRNA-based platform designed to influence plant performance.
Robigo raised new funding to advance engineered microbes that produce and deliver gene-silencing actives.
AgroSpheres and FMC are moving RNA-based bioinsecticides into global field trials using an encapsulated delivery platform.
Silvec Biologics reached a key regulatory milestone with its engineered CTV vector for in-plant expression of antimicrobial proteins.
And GreenLight’s RNA-based fungicide, Oifirax controlling the powdery mildew pathogen in grapes, was approved in Mexico.
Meanwhile, China is building a dedicated regulatory framework for RNA pesticides, has registered its first RNA pesticide (from Silicon Gene, targeting TMV), and recently folded plant RNA pesticide technology into a national agricultural technology-development program.
These are very different stories. But viewed together, they point to the same underlying shift: RNA in agriculture is evolving from a new class of pesticide active ingredients into a broader enabling technology platform.
This is a perspective I explored recently at BioEx, where conversation around RNA biopesticides has clearly moved past proof-of-concept and into the harder questions of efficacy, regulation, cost, and commercialization.
From RNA as an active ingredient to RNA as a platform
For most of the past decade, the agricultural RNA conversation followed a fairly linear model: identify a critical gene in a pest or pathogen, design an RNA molecule to silence it, and find a way to deliver that RNA to the target.
That model still matters. But it’s no longer the whole story.
Syngenta’s EXORT technology illustrates a different direction. Instead of targeting an external pest or pathogen, the platform uses naturally occurring plant microRNAs to regulate the plant’s own gene expression and performance, shifting RNA’s role from controlling an outside biological threat to regulating the crop itself.
The boundaries for RNA applications could eventually stretch well beyond pest and disease control, into regulating plant physiological pathways, enhancing stress tolerance, improving nutrient-use efficiency, and driving more sustainable yield gains.
It’s still early to know how many of these applications will become successful commercial products. But the direction is telling.
Delivery is becoming part of the technology
Delivery has always been one of the toughest problems in agricultural RNA. The molecule needs to be stable long enough to reach its target, cross relevant biological barriers, and remain active under field conditions, not laboratory settings. Delivery and formulation remain the critical bottleneck between lab-scale efficacy and field-scale performance.
Recent developments show just how differently companies are attacking this problem.
Robigo is using engineered microbes as living production-and-delivery systems, rather than manufacturing an active separately and applying it, the microbial chassis continuously produces and delivers gene-silencing actives where they’re needed.
AgroSpheres takes a different approach entirely. Its partnership with FMC pairs RNA-based bioinsecticides with an encapsulated delivery platform, with two candidates now in global field trials against major lepidopteran pests, including fall armyworm and diamondback moth.
Together, these approaches reinforce a point worth stating plainly: for RNA technologies, delivery is no longer a downstream formulation problem; it’s part of the core product architecture, and increasingly a source of real competitive differentiation.
Biological vectors expand the architecture further
Silvec Biologics adds yet another model. Its engineered Citrus tristeza virus (CTV) platform uses a biological vector to enable citrus trees to produce antimicrobial proteins themselves. Here, RNA isn’t being delivered as a conventional pesticide active ingredient, the RNA viral vector becomes part of an in-plant biological expression system.
This distinction is very important because it shows how quickly the boundaries of the RNA technology landscape are expanding. We’re now seeing multiple distinct architectures emerge side by side:
RNA as the active ingredient
RNA produced and delivered through engineered microbes
RNA protected through advanced formulation and encapsulation
microRNA used to regulate plant biology
RNA viral vectors enabling in-plant production of functional molecules
The common thread isn’t a particular RNA molecule anymore; it’s the growing ability to program biological systems.
From molecules to systems
That shift changes the questions companies need to be asking.
It’s no longer enough to ask: Can we identify an RNA sequence that produces the desired biological effect?
The harder, more decisive questions now are:
Can it be manufactured consistently and economically?
Can it be formulated and delivered effectively?
Can it reach the biological target under real field conditions?
How long does the activity need to persist?
Does the delivery architecture fit existing agricultural practices?
How will regulators classify and evaluate the technology?
Can it scale into a single product, or does it lay the foundation for an entire pipeline?
This is where an interesting scientific discovery and a commercially viable technology platform start to diverge. As I emphasized at BioEx, manufacturing robustness and formulation are still underestimated at the early development stage. Regulators and commercial partners need confidence not just in biological activity, but in production consistency, impurity control, scale-up, formulation stability, and reproducible performance.
Regulatory strategy can’t be an afterthought either. It can’t simply begin once product development is “finished.” Early engagement with regulators helps define what the product actually is, how its mode of action should be evaluated, and what evidence will be required to demonstrate environmental fate, safety, and efficacy.
Precision agriculture could add another layer
There’s a dimension here that deserves more attention: RNA’s inherent specificity creates a natural opening to integrate biological design with precision agriculture.
Deeper integration with precision agriculture could eventually enable RNA to be delivered to the right place, at the right time, at increasingly precise spatial scales. As drone applications, sensing, field-level data, variable-rate technologies, and biological targeting all continue to improve, this becomes more realistic, not less.
The longer-term opportunity, then, may be bigger than simply replacing one conventional pesticide with an RNA-based one. It could mean combining programmable biology with programmable applications.
China signals that the ecosystem is evolving, too
Technology alone doesn’t create a new product category. Regulatory frameworks, manufacturing infrastructure, investment, partnerships, and commercial channels all have to mature around it.
China offers an instructive signal here. The country is building dedicated registration requirements specifically for RNA pesticides. Its first RNA pesticide moved through registration quickly. And plant RNA pesticide technology has now been written into a national agricultural technology-development program.
China also holds real advantages in manufacturing and supply chains, and the ongoing challenge of translating strong academic research into reliable field performance and commercial products.
These developments shouldn’t be overstated and regulatory recognition doesn’t guarantee commercial success. But they do suggest RNA crop protection is increasingly being treated as its own identifiable technology category, rather than a scattered set of research projects.
Building an enabling ecosystem
Perhaps the most important transition underway is from individual technologies to a connected ecosystem.
Sequence design alone won’t determine the future of agricultural RNA. Neither will manufacturing, delivery, regulation, or commercialization in isolation. The real opportunity depends on connecting capabilities across the full development chain:
target identification → sequence design → biological system and delivery architecture → manufacturing → formulation → regulatory strategy → field validation → grower adoption → commercialization.
This is also why regulatory harmonization matters so much. Greater international alignment around science-based requirements, particularly around mode of action and environmental safety could meaningfully improve the economics of global RNA product development. A future where appropriate data packages earn broader recognition across jurisdictions could cut unnecessary duplication and help promising technologies reach farmers faster.
That remains an aspiration rather than today’s reality. But it’s a necessary part of building the ecosystem this technology will need.
The next chapter of agricultural RNA
At Nexus BioStrategy, we believe these developments point to a broader way of thinking about RNA innovation. RNA shouldn’t be viewed only as another class of pesticide active ingredients; it has the potential to become an enabling technology platform for agriculture as a whole.
When scalable RNA manufacturing, precise application methods, and a broader biological vision start to converge, RNA is no longer simply a product and starts becoming a platform with far wider possibilities.
The recent moves from Syngenta, Robigo, AgroSpheres/FMC, and Silvec each illustrate a different piece of that emerging landscape. China’s regulatory and innovation developments show that the institutional environment is starting to evolve alongside the technology itself.
There’s still a great deal to prove on field performance, economics, scale, regulatory pathways, and grower adoption. But the direction is becoming clearer.
The next chapter of agricultural RNA won't be won by a single molecule, product, or delivery method. It will be won by integration: connecting RNA biology, delivery, manufacturing, precision agriculture, regulation, and commercialization into systems that scale.
That's how promising science becomes a platform, and how a platform becomes real impact in the field.
